Comparable effects of inhaled fluticasone propionate and budesonide on the HPA-axis in adult asthmatic patients

Respiratory Medicine

Volumn 94, Issue 5, 2000, Pages 482-489

  Ringdal, N ^a   Lundback B ^b,c   Alton, M ^d   Rak, S ^e   Eivindson, A ^f   Bratten, G ^g   Kjaersgaard, P ^g  

^a Molde Internal Medicine Centre   (Norway)

^b Boden Hospital   (Sweden)

^c NATIONAL INSTITUTE FOR WORKING LIFE   (Sweden)

^d ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f Havblik Specialist Centre   (Norway)

^g GLAXOSMITHKLINE   (United States)

Author keywords

Budesonide; Fluticasone propionate; HPA axis

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0342368717     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.1999.0758     Document Type: Article

References (38)

1. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 52:1997;1-34.
2. National Heart, Lung, and Blood Institute, National Institutes of Health. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. NHLB/WHO Workshop Report, January 1995.
3. Thorax. 52:1997;S1-S24.
4. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay A Y. Purpura and dermal thinning associated with high-dose inhaled corticosteroids. Br Med J. 300:1990;1548-5l.
5. Mak V, Melchor R, Spiro S G. Easy bruising as a side effect of inhaled corticosteroids. Eur Respir J. 5:1992;1068-1074.
6. Hanania N A, Chapman K R, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 98:1995;196-208.
7. Geddes D. Inhaled corticosteroids: benefits and risks. Thorax. 47:1992;404-406.
8. Barnes P J, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis. 148:1993;S1-S26.
9. Clark D J, Lipworth B J. Dose-response of inhaled drugs in asthma. Clin Pharmacokinet. 32:1997;58-74.
10. Brattsand R, Ingelf J. Pharmacodynamic and pharmacokinetic basis for inhaled glucocorticosteroid (GCS) therapy in allergic rhinitis. Mellilo G, O'Byrne P M, Marone G. Respiratory Allergy: Advances in Clinical Immunology and Pulmonary Medicine. 1993;129-136 Elsevier, Amsterdam.
11. Brattsand R. Development of glucocorticoids with lung selectivity. Hargreave F E, Hogg J C, Malo J-L, Toogood J H. Glucocorticoids and Mechanisms of Asthma. 1989;17-38 Excerpta Medica, Amsterdam.
12. Andersson N, Klint S, Randwall G, Wirén J E. Equipotency of BUD and fluticasone propionate in the vasoconstriction assay. Am J Respir Crit Care Med. 149:1994;A467.
13. Phillips G H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 84:1990;19-23.
14. Harding S M. The human pharmacology of fluticasone propionate. Respir Med. 84:1990;25-29.
15. Umland S P, Nahrebna D K, Rasac S. Effects of mometasone furoate and other glucocorticoids on cytokine production from cultured peripheral blood CD4+T cells. J Allergy Clin Immunol. 97:1996;A423.
16. Kita, H, Hagen, J, B, Gleich, G, J, Fluticasone propionate is the most potent glucocorticoid in the induction of apoptosis of eosinophils, Acute and Chronic Inflammation in the Respiratory Tract. International Respiratory Forum, London, Colwood Publishing, 1995, 73.
17. Schroeder, J, T, Stellato, C, Lichtenstein, L, M, Bickel, C, A, Schleimer, R, P, Regulation of human basophil histamine release and IL-4 secretion by glucocorticoids, Acute and Chronic Inflammation in the Respiratory Tract. International Respiratory Forum, London, Colwood Publishing, 1995, 79.
18. Leblanc P, Mink S, Keistinen T, Saarelainen P A, Ringdal N, Payne S L. A comparison of fluticasone propionate 200 μ g/day with beclomethasone 400 μ g/day in adult asthma. Allergy. 49:1994;380-385.
19. -1) administered by pressurized inhaler. Respir Med. 87:1993;609-620.
20. Langdon C G, Capsey L J. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhalation devices. Br J Clin Res. 5:1995;85-99.
21. Langdon C G, Thompson J. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered-dose inhalers in adults with mild-to-moderate asthma. Br J Clin Res. 5:1994;73-84.
22. TMinhaler in adult asthmatics. J Allergy Clin Immunol. 97:1996;A267.
23. Ringdal N, Swinburn P, Backman R. A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation. Mediators Inflamm. 5:1996;382-389.
24. Fabbri L, Burge P S, Croonenborgh L. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax. 48:1993;817-823.
25. Ayres J G, Bateman E D, Lundbäck B, Harris T AJ. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate 2 mg daily, or budesonide 1·6 mg daily, in patients with chronic severe asthma. Eur Respir J. 8:1995;579-586.
26. Bye A. The oral systemic bioavailability of fluticasone propionate in man - preliminary data. Br J Clin Pharmacol. 36:1993;136.
27. Falcoz C, Mackie A E, McDowall J, McRae J, Yogendran L, Ventresca G P, Bye A. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 41:1996;459-60P.
28. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J. 9:1996;1427-1432.
29. Senn S. Cross-over Trials in Clinical Research. 1993;John Wiley & Sons Ltd. London. p. 31-70.
30. Barnes N C, Hallett C, Harris T AJ. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med. 92:1998;95-104.
31. ®powder devices in asthmatic patients. Br J Clin Pharmacol. 43:1997;541P.
32. ®powder devices in healthy subjects. Br J Clin Pharmacol. 43:1997;540P.
33. Dluhy R G. Assessment of systemic corticosteroid activity. Respir Med. 91:1997;32-33.
34. TMin patients with chronic severe asthma. Eur Respir J. 10:1997;172-173.
35. Clark D J, Lipworth B J. Adrenal suppression with chronic dosing of fluticasone propinate compared with budesonide in adult asthmatic patients. Thorax. 52:1997;55-58.
36. 1998.
37. Bjermer L, Walstad R. Effect on HPA axis and on osteacin production by inhaled budesonide (BUD) and fluticasone dipropionate (FP) given by multi dose powder inhalers. Am J Respir Crit Care Med. 155:1997;A356.
38. Grahnen A, Eckernaes S Å, Brundin R M, Ling-Andersen A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol. 38:1994;521-525.